Drug Trial Radar · NCT07386938
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
246
Planned (sponsor's estimate)
Start
Aug 9, 2024
Primary completion
Oct 15, 2025
Study completion May 28, 2027
Sponsor
- Lead sponsor
- R-PharmIndustry
- Sponsor type
- Industry
- First posted
- Feb 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to prove non-inferiority, as well as to demonstrate the comparability of safety and immunogenicity of RPH-051 and Perjeta® in combination with trastuzumab and docetaxel as the 1st line therapy for patients with HER2-positive breast cancer (BC). Secondary Purposes are to evaluate the pharmacokinetics of RPH-051 in comparison with Perjeta® after a single-dose and repeated intravenous administration
Conditions
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
Interventions
RPH-051Drug
RPH-051: concentrate for solution for infusion, 30 mg/mL 14 mL of the liquid concentrate is diluted with 250 mL of 0.9% sodium chloride solution. The nominal concentration of the prepared solution is 3.0 mg/mL for the loading dose and 1.6 mg/mL for the maintenance dose
DocetaxelDrug
Docetaxel: concentrate for solution for infusion, 20 mg/mL
Perjeta®Drug
Perjeta®: concentrate for solution for infusion, 30 mg/mL 14 mL of the liquid concentrate is diluted with 250 mL of 0.9% sodium chloride solution. The nominal concentration of the prepared solution is 3.0 mg/mL for the loading dose and 1.6 mg/mL for the maintenance dose
TrastuzumabDrug
Trastuzumab: lyophilisate for preparation of a concentrate for solution for infusion, 440 mg or 150 mg The contents of the vial (440 mg) are dissolved in 20 mL of bacteriostatic water for injection supplied with the drug, containing 1.1% benzyl alcohol. The contents of the vial (150 mg) are dissolved in 7.2 mL of sterile water for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (%) (ORR)Time frame: Up to day 126
Locations
45 sites in 1 country. Site status is shown where the registry gives one.
State Budgetary Healthcare Institution of Arkhangelsk Region "Arkhangelsk Clinical Oncology Dispensary"
Arkhangelsk, Russia
Regional State Budgetary Healthcare Institution "Altai Regional Oncology Dispensary"
Barnaul, Russia
Private Healthcare Institution "RZD-Medicine Clinical Hospital of Chelyabinsk"
Chelyabinsk, Russia
Regional Budgetary Healthcare Institution "Ivanovo Regional Oncology Dispensary" (RBHI "IvOOD")
Ivanovo, Russia
State Budgetary Healthcare Institution of Kaluga Region "Kaluga Regional Clinical Oncology Dispensary"
Kaluga, Russia
State Autonomous Healthcare Institution "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"
Kazan', Russia
State Budgetary Healthcare Institution "Kuzbass Clinical Oncology Dispensary named after M.S. Rappoport" (SBHI "KCOD")
Kemerovo, Russia
Kirov Regional State Clinical Budgetary Healthcare Institution "Center of Oncology and Medical Radiology"
Kirov, Russia
Regional State Budgetary Healthcare Institution "Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky"
Krasnoyarsk, Russia
State Budgetary Healthcare Institution of the City of Moscow "Moscow Multidisciplinary Clinical Center 'Kommunarka' of the Moscow Department of Healthcare" (SBHI "MMCC 'Kommunarka'")
Moscow, Russia
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation
Moscow, Russia
Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University)
Moscow, Russia
Branch of the Limited Liability Company "Hadassah Medical Ltd." (LLC Branch "Hadassah Medical")
Moscow, Russia
Federal State Autonomous Institution "National Medical Research Center 'Medical and Rehabilitation Center'" of the Ministry of Health of the Russian Federation
Moscow, Russia
Limited Liability Company "RESEARCH LAB"
Moscow, Russia
State Budgetary Healthcare Institution of the City of Moscow "City Clinical Hospital named after S.S. Yudin" of the Moscow Department of Healthcare
Moscow, Russia
Joint-Stock Company "Medsi Group of Companies" (JSC "Medsi Group of Companies")
Moscow, Russia
Federal State Budgetary Institution "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation
Moscow, Russia
Private Medical Institution "Euromedservice" (PMI "Euromedservice")
Moscow, Russia
State Budgetary Healthcare Institution of the City of Moscow "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of the Moscow Department of Healthcare"
Moscow, Russia
Limited Liability Company "Novaya Liniya"
Nal'chik, Russia
State Autonomous Healthcare Institution of the Nizhny Novgorod Region "Research Institute of Clinical Oncology 'Nizhny Novgorod Regional Clinical Oncology Dispensary'"
Nizhny Novgorod, Russia
Limited Liability Company Medical and Sanitary Unit "Clinician-Pretor Clinic"
Novosibirsk, Russia
Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of the Russian Federation
Obninsk, Russia
Federal State Budgetary Healthcare Institution "Clinical Hospital No. 8 of the Federal Medical-Biological Agency" (FSBHI CH No. 8 FMBA)
Obninsk, Russia
Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary"
Omsk, Russia
State Budgetary Healthcare Institution of Perm Krai "Perm Krai Oncology Dispensary"
Perm, Russia
State Budgetary Healthcare Institution of Stavropol Krai "Pyatigorsk Interdistrict Oncology Dispensary"
Pyatigorsk, Russia
Federal State Budgetary Institution "National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation
Rostov-on-Don, Russia
Joint-Stock Company "Modern Medical Technologies"
Saint Petersburg, Russia
Limited Liability Company "EuroCityClinic"
Saint Petersburg, Russia
Federal State Budgetary Institution "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation
Saint Petersburg, Russia
State Budgetary Healthcare Institution "St. Petersburg Clinical Scientific and Practical Center for Specialized Medical Care (Oncology) named after N.P. Napalkov"
Saint Petersburg, Russia
Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncology Dispensary" (SPB SBHI CCOD)
Saint Petersburg, Russia
State Healthcare Institution "Regional Clinical Oncology Dispensary" (SHI "RCOD")
Saratov, Russia
Regional State Budgetary Healthcare Institution "Smolensk Regional Oncology Clinical Dispensary"
Smolensk, Russia
Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation
Tomsk, Russia
Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences" (FSBSI "Tomsk NRMC of the Russian Academy of Sciences")
Tomsk, Russia
State Healthcare Institution "Tula Regional Clinical Oncology Dispensary" (SHI "TRCOD")
Tula, Russia
State Autonomous Healthcare Institution "Republican Clinical Oncology Dispensary" of the Ministry of Health of the Republic of Bashkortostan
Ufa, Russia
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.